Ftse Mib
34.305,35
-0,03%
DAX
20.278,93
0,12%
S&P 500
6.050,61
-0,39%
NASDAQ
20.109,06
-0,32%
Bitcoin
103.861,00
-2,16%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Regulus Therapeutics Inc (RGLS) Regulus Therapeutics Inc (RGLS) Notizie

RGLS

Regulus Therapeutics (RGLS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RGLS
DataOraFonteTitoloSimboloCompagnia
26/11/202414:00PR Newswire (US)Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/11/202420:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
08/10/202414:00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
28/08/202414:00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/08/202422:05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/08/202414:00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
29/07/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202416:00AllPennyStocks.comThis Biotech Wasted No Time Stealing The Premarket ShowNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202413:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
04/06/202414:00PR Newswire (US)Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesNASDAQ:RGLSRegulus Therapeutics Inc
20/05/202422:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
16/05/202414:00PR Newswire (US)Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerNASDAQ:RGLSRegulus Therapeutics Inc
09/05/202422:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGLSRegulus Therapeutics Inc
09/05/202422:05PR Newswire (US)Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/05/202414:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
30/04/202414:00PR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
21/03/202421:05PR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202411:32PR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
12/03/202411:30PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
10/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
02/01/202422:05PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
27/12/202322:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
22/11/202314:00PR Newswire (US)Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
09/11/202322:05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
02/11/202313:00PR Newswire (US)Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
19/10/202314:00PR Newswire (US)Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
20/09/202313:00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RGLS

La tua Cronologia

BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
TIT
Telecom Italia
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
BAMI
Banco BPM
BIT
AZM
Azimut Hldg
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
LDO
Leonardo
BIT
NEXI
Nexi S.p.A
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network